| 包装 | 价格(元) |
| 1mg | 电议 |
| 5mg | 电议 |
Cell lines | U266B1 cells |
Preparation Method | Cell Proliferation Assays U266B1 cells were suspended with SOMAmer (1, 10, or 100 μg/ml) or tocilizumab (1, 10, or 100 μg/ml) in RPMI 1640 medium containing 10% FBS at 104 cells per well and cultured for 30 min at 37 ℃ in a 5% CO2 incubator. |
Reaction Conditions | 1, 10, or 100 μg/ml，30 min at 37 ℃ |
Applications | SL1026 achieved complete inhibition of IL-6 at 1 μg/ml (83 nm), whereas tocilizumab achieved 60% inhibition at a roughly equivalent molar concentration (67 nm) . |
Animal models | Patients with rheumatoid arthritis |
Preparation Method | Patients (n=1262) were randomised 1:1 to receive Tocilizumab-SC 162 mg weekly (qw)+placebo-IV every four weeks (q4w) or Tocilizumab-IV 8 mg/kg q4w+placebo-SC qw in combination with DMARD(s). Maintenance of clinical responses and safety through week 97 were assessed. |
Dosage form | 8 mg/kg; SC,IV |
Applications | Tocilizumab-SC had a comparable safety profile to Tocilizumab-IV through week 97, except that injection site reactions (ISRs) were more common with Tocilizumab-SC. Safety profiles in patients who switched were similar to those in patients who received continuous Tocilizumab-SC or Tocilizumab-IV treatment. |
| 产品描述 | Tocilizumab, as a humanised monoclonal antibody, can target both membrane-bound and soluble forms of the IL-6 receptor.[1]Tocilizumab has been approved for treatment in patients with rheumatologic disorders and chimeric antigen receptor T cell-induced cytokine release syndrome.[3] In vitro efficacy test it shown that treatment with tocilizumab (1 or 10 μm) or SOMAmer (0.83 or 8.3 μm), SOMAmer suppressed the proliferation of U87MG and HepG2 cells to a greater extent than tocilizumab at similar molar concentrations.[7] In vivo efficacy test it indicated that treatment with 8 mg/kg tocilizumab using two consecutive intravenous infusions 12 h apart in 100 patients with COVID-19 and ARDS requiring ventilatory support in Brescia (Italy) has 20% mortality according to an optional third infusion based on clinical response.[1]In vivo, tocilizumab 8 mg/kg × 1 in mechanically ventilated patients, the results shown that receipt of tocilizumab was independently associated with improved survival.[2]In vivo study for the treatment of rheumatoid arthritis, treatment with 4 mg/kg tocilizumab, the results exhibited that the average IL-6 level reached the peak at the second week after administration, and then decreased gradually.[4]In a 61-year-old man with COVID-19, treatment with 324 mg Tocilizumab via subcutaneous with hydroxychloroquine can successfully manage the infection.[6]In addition, the recommended dose of Tocilizumab is 4–8 mg/kg administered as a single 60- minute intravenous infusion every 4 weeks for treatment in moderate to severe active arthritis in adults, Giant cell arthritis, Polyarticular juvenile idiopathic arthritis and cytokine release syndrome in patients 2 years of age older with active disease.[5] References: |
m.cnreagent.com